Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹319.00 crores, reported a consolidated net profit of ₹32.26 crores for Q1 FY27, representing a remarkable year-on-year growth of 14.07% from ₹28.28 crores in Q1 FY26. However, the stock has declined 1.47% following the results announcement, closing at ₹161.15, as investors grapple with the company's persistent quality challenges and weak long-term fundamental strength.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with the most up-to-date analysis.

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This adjustment reflects a complex interplay of factors including a shift in technical indicators, subdued financial trends, valuation considerations, and overall quality assessments. Despite a modest uptick in share price, the company’s long-term fundamentals and market performance continue to raise concerns for investors.

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 15 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to face challenges in long-term growth and profitability, recent technical indicators and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.

Nath Bio-Genes (India) Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 8 June 2026, reflecting concerns over its stagnant financial performance, weak long-term fundamentals, and consistent underperformance against market benchmarks. Despite a very attractive valuation, the company’s deteriorating financial trends and technical indicators have prompted a cautious stance from analysts.

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 1 June 2026. This change reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite persistent challenges in long-term fundamentals, recent technical signals and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.

The 50-day moving average for Nath Bio-Genes (India) Ltd has crossed above the 200-day moving average, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that merits careful analysis.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd has reported a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales have shown robust growth, profitability metrics and earnings per share continue to face headwinds, reflecting a complex financial landscape for this micro-cap player in the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹330.86 crores, reported a shocking loss of ₹0.01 crores for Q4 FY26, marking a complete reversal from the ₹0.94 crores profit posted in Q4 FY25. The stock plunged 7.87% on May 5, 2026, closing at ₹174.45, as investors reacted to an extraordinary tax charge that exceeded the company's pre-tax profit—a rare accounting anomaly that signals potential earnings quality concerns.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.